Pharmacological strategies for the management of comorbid depression and schizophrenia
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F20%3AA21028AG" target="_blank" >RIV/61988987:17110/20:A21028AG - isvavai.cz</a>
Alternative codes found
RIV/00216224:14740/20:00115688 RIV/65269705:_____/20:00072698 RIV/00843989:_____/20:E0108379
Result on the web
<a href="https://www.tandfonline.com/doi/full/10.1080/14656566.2020.1717466" target="_blank" >https://www.tandfonline.com/doi/full/10.1080/14656566.2020.1717466</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1080/14656566.2020.1717466" target="_blank" >10.1080/14656566.2020.1717466</a>
Alternative languages
Result language
angličtina
Original language name
Pharmacological strategies for the management of comorbid depression and schizophrenia
Original language description
Depressive symptoms may occur in any phase of schizophrenia and can have far-reaching consequences. Areas covered: The author focuses on recent reviews and meta-analyses dealing with the prevalence, importance, etiopathogenesis, and pharmacotherapy of comorbid depression and schizophrenia. Depressive symptoms in acute episodes may improve in parallel with psychosis due to antipsychotic treatment. Therefore, the first step is to evaluate the current antipsychotic treatment of psychotic symptoms and consider changing the dosage. A second step is switching antipsychotic medications, since there are indications that some medications are slightly more effective in reducing depressive symptoms than others. For persistent depressive episodes, additional therapeutic interventions are indicated. Most guidelines recommend the administration of antidepressants as an add-on treatment with a limited evidence level. Immunotherapeutic strategies could be successful, at least in some schizophrenia patients. Expert opinion: In the near future, precision psychiatry should enable clinicians to recognize specific biotypes with unique biosignatures that will guide accurate and prompt clinical management for individual patients.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30104 - Pharmacology and pharmacy
Result continuities
Project
<a href="/en/project/LQ1601" target="_blank" >LQ1601: CEITEC 2020</a><br>
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
EXPERT OPINION ON PHARMACOTHERAPY
ISSN
1465-6566
e-ISSN
—
Volume of the periodical
21
Issue of the periodical within the volume
4
Country of publishing house
GB - UNITED KINGDOM
Number of pages
7
Pages from-to
459-465
UT code for WoS article
000509444600001
EID of the result in the Scopus database
—